Cancer immunotherapy in clinical oncology

Cancer Chemotherapy and Pharmacology

Volumn 46, Issue SUPPL., 2000, Pages

  Knuth, A ^a   Jager, D ^a   Jager, E ^a  

^a KRANKENHAUS NORDWEST   (Germany)

Author keywords

Peptide immunization; T cell responses; Tumor antigens

Indexed keywords

DIFFERENTIATION ANTIGEN; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; INTERLEUKIN 12; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; MELANOMA ANTIGEN 1; MELANOMA ANTIGEN 3; NY ESO 1 ANTIGEN; TUMOR ANTIGEN; TUMOR VACCINE; UNCLASSIFIED DRUG; VIRUS ANTIGEN;

ANTIGEN EXPRESSION; ANTIGEN RECOGNITION; ARTICLE; CANCER IMMUNIZATION; CANCER IMMUNOTHERAPY; CELLULAR IMMUNITY; CYTOTOXIC T LYMPHOCYTE; DELAYED HYPERSENSITIVITY; DENDRITIC CELL; HUMAN; IMMUNOGENICITY; POINT MUTATION; PRIORITY JOURNAL; TUMOR REGRESSION;

EID: 0033758828     PISSN: 03445704     EISSN: None     Source Type: Journal    
DOI: 10.1007/pl00014050     Document Type: Article

References (60)

1. Dendritic cells generated from peripheral blood transfected with human tyrosinase induce specific T cell activation
2. Melanocyte lineage-specific antigen gp100 is recognized by melanoma-derived tumor-infiltrating lymphocytes
3. Tumor antigens recognized by cytolytic T cells
4. Expression of MAGE genes in primary and metastatic cutaneous melanoma
5. The tyrosinase gene codes for an antigen recognized by autologous cytolytic T lymphocytes on HLA-A2 melanomas
6. GM-CSF and TNFα cooperate in the generation of dendritic Langerhans cells
7. Immunophenotyping of melanomas for tyrosinase: Implications for vaccine development
8. Serological analysis of Melan A (MART-1), a melanocyte-specific protein homogenously expressed in human melanomas
9. A testicular antigen aberrantly expressed in human cancers detected by autologous antibody screening
10. A mutated intron sequence codes for an antigenic peptide recognized by cytolytic T lymphocytes on a human melanoma
11. A new gene coding for a differentiation antigen recognized by autologous cytolytic T lymphocytes on HLA-A2 melanomas
12. Oncogenic proteins as tumor antigens
13. Vaccination with irradiated tumor cells engineered to secrete murine granulocyte-macrophage colony-stimulating factor stimulates potent, specific, and long-lasting anti-tumor immunity
14. Vaccination with cytotoxic T lymphocyte epitope-containing peptide protects against a tumor induced by human papillomavirus type 16-transformed cells
15. Induction of T-cell immunity against Ras oncoprotein by soluble protein or Ras-expressing Escherichia coli
16. Human gene MAGE-3 codes for an antigen recognized on a melanoma by autologous cytolytic T lymphocytes
17. Vaccination with mutant Ras peptides and induction of T-cell responsiveness in pancreatic carcinoma patients carrying the corresponding Ras mutation
18. The regressing thin malignant melanoma: A distinctive lesion with metastatic potential
19. Frequency analysis of tumor-reactive cytotoxic T lymphocytes in peripheral blood of a melanoma patient vaccinated with autologous tumor cells
20. Identification of NY-ESO- 1 epitopes presented by HLA-DRB4 0101-0103 and recognized by CD4+ T lymphocytes of patients with NY-ESO-1 expressing melanoma
21. Humoral immune responses of cancer patients against 'Cancer-Testis antigen NY-ESO-1: Correlation with clinical events
22. Generation of cytotoxic T cell responses with synthetic melanoma associated peptides in vivo: Implications for tumor vaccines with melanoma associated antigens
23. Clonal expansion of Melan A-specific cytotoxic T lymphocytes (CTL) in a melanoma patient responding to continued immunization with melanoma-associated peptides
24. Granulocyte macrophage colony-stimulating factor enhances immune responses to melanoma associated peptides in vivo
25. Inverse relationship of melanocyte differentiation antigen expression in melanoma: Evidence for immunoselection of antigen-loss variants in vivo
26. Immunoselection in vivo: Independent loss of MHC class 1 and melanocyte differentiation antigen expression in metastatic melanoma mediated by antigen-specific CTL
27. Cytolytic T cell reactivity against melanoma associated differentiation antigens in peripheral blood of melanoma patients and healthy individuals
28. Simultaneous humoral and cellular immune response against Cancer-Testis Antigen NY-ESO-1: Definition of human histocompatibility leucocyte antigen (HLA)-A2-binding peptide epitopes
29. Identification of a tyrosinase epitope recognized by HLA-A24-restricted, tumorinfiltrating lymphocytes
30. Identification of a human melanoma antigen recognized by tumor-infiltrating lymphocytes associated with in vivo tumor rejection
31. Cloning of the gene coding for a shared human melanoma antigen recognized by autologous T cells infiltrating into tumor
32. Recognition of multiple epitopes in the human melanoma antigen gp100 by tumor-infiltrating lymphocytes associated with in vivo tumor regression
33. T-cell-mediated cytotoxicity against autologous malignant melanoma: Analysis with interleukin-2-dependent T-cell cultures
34. Cellular and humoral responses against cancer: Implications for cancer vaccines
35. T cell responses to human malignant tumours
36. Cytolytic T-cell clones against an autologous human melanoma: Specificity study and definition of three antigens by immunoselection
37. Characterization of MHC class I restricted cytotoxic T cell responses to tax in HTLV-1 infected patients with neurologic disease
38. HLA-class I-restricted cytotoxic T lymphocytes specific for hepatitis C virus. Identification of multiple epitopes and characterization of patterns of cytokine release
39. CTL induction by a tumour-associated antigen octapeptide derived from a murine lung carcinoma
40. Tumor regression responses in melanoma patients treated with a peptide encoded by gene MAGE-3
41. Tolerance, danger, and the extended family
42. Identification of target antigens for the human cytotoxic T cell response to Epstein-Barr virus-(EBV): Implications for the immune control of EBV-positive malignancies
43. Influence of interleukin-12 on p53 peptide vaccination against established Meth A sarcoma
44. High frequency of skin-homing melanocyte-specific cytotoxic T lymphocytes in autoimmune vitiligo
45. The cytotoxic T lymphocyte response to multiple hepatitis B virus polymerase epitopes during and after acute viral hepatitis
46. Induction of tumor-reactive CTL from peripheral blood and tumor-infiltrating lymphocytes of melanoma patients by in vitro stimulation with an immunodominant peptide of the human melanoma antigen MART-1
47. Recognition of tyrosinase by tumor-infiltrating lymphocytes from a patient responding to immunotherapy
48. Human neoplasms elicit multiple specific immune responses in the autologous host
49. Hepatitis B virus small surface antigen particles are processed in a novel endosomal pathway for major histocompatibility complex class Irestricted epitope presentation
50. Antibodies against p53 in breast cancer patients is directed against immunodominant epitopes unrelated to the mutational hot spot
51. A survey of the humoral immune response of cancer patients to a panel of human tumor antigens
52. Primary proliferative T cell response to wild-type p53 protein in patients with breast cancer
53. A nonapeptide encoded by human gene MAGE-1 is recognized on HLA-Al by cytolytic T-lymphocytes directed against tumor antigen MZ2-E
54. A new family of genes coding for an antigen recognized by autologous cytolytic T lymphocytes on a human melanoma
55. A gene encoding an antigen recognized by cytolytic T lymphocytes on a human melanoma
56. CTL specific for the tyrosinase autoantigen can be induced from healthy donor blood to lyse melanoma cells
57. Lysis of human melanoma cells by autologous cytolytic T cell clones. Identification of human histocompatibility leukocyte antigene A2 as a restriction element for three different antigens
58. Isolation of naturally processed peptides recognized by cytolytic T lymphocytes (CTL) on human melanoma cells in association with HLA-A2.1
59. A p16INK4a-insensitive CDK4 mutant targeted by cytolytic T lymphocytes in a human melanoma